Published in J Clin Microbiol on May 14, 2008
Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis (2011) 2.19
Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin. Proc Natl Acad Sci U S A (2012) 2.18
Interval Between Infections and Viral Hierarchy Are Determinants of Viral Interference Following Influenza Virus Infection in a Ferret Model. J Infect Dis (2015) 1.50
Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment. Antimicrob Agents Chemother (2013) 1.39
Receptor specificity of influenza A H3N2 viruses isolated in mammalian cells and embryonated chicken eggs. J Virol (2010) 1.21
Antigenic drift of the pandemic 2009 A(H1N1) influenza virus in A ferret model. PLoS Pathog (2013) 1.20
Human H3N2 Influenza Viruses Isolated from 1968 To 2012 Show Varying Preference for Receptor Substructures with No Apparent Consequences for Disease or Spread. PLoS One (2013) 1.07
Sialic acid recognition is a key determinant of influenza A virus tropism in murine trachea epithelial cell cultures. Virology (2009) 1.02
Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques. J Virol (2009) 0.96
Identification of traditional medicinal plant extracts with novel anti-influenza activity. PLoS One (2013) 0.90
Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs. Clin Vaccine Immunol (2012) 0.89
Recent H3N2 influenza virus clinical isolates rapidly acquire hemagglutinin or neuraminidase mutations when propagated for antigenic analyses. J Virol (2014) 0.85
In vivo and in vitro alterations in influenza A/H3N2 virus M2 and hemagglutinin genes: effect of passage in MDCK-SIAT1 cells and conventional MDCK cells. J Clin Microbiol (2008) 0.85
A novel video tracking method to evaluate the effect of influenza infection and antiviral treatment on ferret activity. PLoS One (2015) 0.84
Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production. Proc Natl Acad Sci U S A (2009) 0.84
Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact. J Antimicrob Chemother (2014) 0.83
Exploring cell tropism as a possible contributor to influenza infection severity. PLoS One (2010) 0.82
Retrospective investigation of an influenza A/H1N1pdm outbreak in an Italian military ship cruising in the Mediterranean Sea, May-September 2009. PLoS One (2011) 0.82
Recent H3N2 Viruses Have Evolved Specificity for Extended, Branched Human-type Receptors, Conferring Potential for Increased Avidity. Cell Host Microbe (2016) 0.81
Characterization of the Localized Immune Response in the Respiratory Tract of Ferrets following Infection with Influenza A and B Viruses. J Virol (2015) 0.79
Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada. Influenza Other Respir Viruses (2016) 0.78
Optimization of a micro-neutralisation assay and its application in antigenic characterisation of influenza viruses. Influenza Other Respir Viruses (2015) 0.78
Detection of influenza antigenic variants directly from clinical samples using polyclonal antibody based proximity ligation assays. Virology (2014) 0.78
Application of a seven-target pyrosequencing assay to improve the detection of neuraminidase inhibitor-resistant Influenza A(H3N2) viruses. Antimicrob Agents Chemother (2015) 0.78
Glycosylation changes in the globular head of H3N2 influenza hemagglutinin modulate receptor binding without affecting virus virulence. Sci Rep (2016) 0.78
Distinct susceptibility and applicability of MDCK derivatives for influenza virus research. PLoS One (2017) 0.77
Effects of egg-adaptation on receptor-binding and antigenic properties of recent influenza A (H3N2) vaccine viruses. J Gen Virol (2016) 0.77
Genetic and antigenic typing of seasonal influenza virus breakthrough cases from a 2008-2009 vaccine efficacy trial. Clin Vaccine Immunol (2013) 0.77
Identification of different respiratory viruses, after a cell culture step, by matrix assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS). Sci Rep (2016) 0.76
Detection of nonhemagglutinating influenza a(h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus culture. J Clin Microbiol (2014) 0.76
Sequence amplification via cell passaging creates spurious signals of positive adaptation in influenza virus H3N2 hemagglutinin. Virus Evol (2016) 0.76
The characteristics and antigenic properties of recently emerged subclade 3C.3a and 3C.2a human influenza A(H3N2) viruses passaged in MDCK cells. Influenza Other Respir Viruses (2017) 0.75
Cellular and humoral cross-immunity against two H3N2v influenza strains in presumably unexposed healthy and HIV-infected subjects. PLoS One (2014) 0.75
COBRA HA elicits hemagglutination-inhibition antibodies against a panel of H3N2 influenza virus co-circulating variants. J Virol (2017) 0.75
Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature (1988) 8.32
Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals. J Virol (2000) 8.28
Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology (1983) 7.26
Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol (2003) 5.11
Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med Microbiol Immunol (1975) 4.89
Influenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium; the role of the host cell in selection of hemagglutinin receptor specificity. Virus Res (1993) 4.45
Evidence for host-cell selection of influenza virus antigenic variants. Nature (1983) 4.24
Sialyloligosaccharides of the respiratory epithelium in the selection of human influenza virus receptor specificity. Acta Histochem Suppl (1990) 3.12
Receptor specificity of influenza A viruses correlates with the agglutination of erythrocytes from different animal species. Virology (1997) 3.10
Replication and plaque assay of influenza virus in an established line of canine kidney cells. Appl Microbiol (1968) 3.04
Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology (1985) 2.71
Change in receptor-binding specificity of recent human influenza A viruses (H3N2): a single amino acid change in hemagglutinin altered its recognition of sialyloligosaccharides. Virology (2000) 2.70
Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus. Virology (1987) 2.58
Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J Clin Microbiol (2005) 2.55
Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. J Virol (1990) 2.45
Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. J Virol (1997) 2.38
Effects of egg-adaptation on the receptor-binding properties of human influenza A and B viruses. Virology (1999) 2.31
Canine kidney cell line for isolation of respiratory viruses. J Clin Microbiol (1979) 2.25
Hemagglutinin residues of recent human A(H3N2) influenza viruses that contribute to the inability to agglutinate chicken erythrocytes. Virology (2001) 2.11
Comparison of 10 influenza A (H1N1 and H3N2) haemagglutinin sequences obtained directly from clinical specimens to those of MDCK cell- and egg-grown viruses. J Gen Virol (1993) 1.92
Permanent canine kidney (MDCK) cells for isolation and plaque assay of influenza B viruses. Med Microbiol Immunol (1975) 1.89
African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses. J Virol (1996) 1.39
Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine (2007) 1.35
Characterization of a porcine lung epithelial cell line suitable for influenza virus studies. J Virol (2001) 1.33
Replication of influenza A viruses in a green monkey kidney continuous cell line (Vero). J Infect Dis (1995) 1.26
Enhanced growth of seed viruses for H5N1 influenza vaccines. Virology (2007) 1.20
Improved colorimetric assay for detecting influenza B virus neutralizing antibody responses to vaccination and infection. J Clin Microbiol (1989) 1.19
Evolutionary characterization of recent human H3N2 influenza A isolates from Japan and China: novel changes in the receptor binding domain. Arch Virol (1996) 1.19
The hemagglutinin of influenza B virus present in clinical material is a single species identical to that of mammalian cell-grown virus. Virology (1990) 1.19
Progress on baculovirus-derived influenza vaccines. Curr Opin Mol Ther (2008) 1.15
Sequence analysis of the haemagglutinin (HA) of influenza A (H1N1) viruses present in clinical material and comparison with the HA of laboratory-derived virus. J Gen Virol (1991) 1.13
Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs. Dev Biol Stand (1999) 1.13
The use of MDCK, MEK and LLC-MK2 cell lines with enzyme immunoassay for the isolation of influenza and parainfluenza viruses from clinical specimens. J Virol Methods (1993) 1.12
Selection of receptor-binding variants of human influenza A and B viruses in baby hamster kidney cells. Virology (1999) 1.09
Distinct host range of influenza H3N2 virus isolates in Vero and MDCK cells is determined by cell specific glycosylation pattern. Virology (2003) 0.95
Antigenic alteration of influenza B virus associated with loss of a glycosylation site due to host-cell adaptation. J Med Virol (2004) 0.95
Influenza vaccines. Nat Rev Drug Discov (2006) 0.90
A host restriction-based selection system for influenza haemagglutinin transfectant viruses. J Gen Virol (1998) 0.89
Stabilizing the glycosylation pattern of influenza B hemagglutinin following adaptation to growth in eggs. Vaccine (2007) 0.89
A new European perspective of influenza pandemic planning with a particular focus on the role of mammalian cell culture vaccines. Vaccine (2005) 0.83
The global circulation of seasonal influenza A (H3N2) viruses. Science (2008) 10.05
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res (2009) 3.39
Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science (2013) 3.38
2009 influenza A(H1N1) seroconversion rates and risk factors among distinct adult cohorts in Singapore. JAMA (2010) 3.05
Performance of influenza rapid point-of-care tests in the detection of swine lineage A(H1N1) influenza viruses. Influenza Other Respir Viruses (2009) 2.75
Performance of six influenza rapid tests in detecting human influenza in clinical specimens. J Clin Virol (2007) 2.62
Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol (2009) 2.59
Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine (2008) 2.56
Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res (2004) 1.98
Efficacy of soap and water and alcohol-based hand-rub preparations against live H1N1 influenza virus on the hands of human volunteers. Clin Infect Dis (2009) 1.67
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother (2009) 1.64
Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model. J Infect Dis (2010) 1.61
Serological response in RT-PCR confirmed H1N1-2009 influenza a by hemagglutination inhibition and virus neutralization assays: an observational study. PLoS One (2010) 1.48
Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci U S A (2009) 1.44
Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs (2009) 1.41
Comparison of the incidence of influenza in relation to climate factors during 2000-2007 in five countries. J Med Virol (2010) 1.36
Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J Virol (2010) 1.31
Cross-reactive antibodies to pandemic (H1N1) 2009 virus, Singapore. Emerg Infect Dis (2010) 1.30
Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology (2008) 1.23
The age-specific cumulative incidence of infection with pandemic influenza H1N1 2009 was similar in various countries prior to vaccination. PLoS One (2011) 1.23
Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs. Virus Res (2004) 1.22
High proportion of influenza B characterises the 2008 influenza season in Victoria. Commun Dis Intell Q Rep (2009) 1.22
Antigenic drift of the pandemic 2009 A(H1N1) influenza virus in A ferret model. PLoS Pathog (2013) 1.20
Response of Porphyromonas gingivalis to heme limitation in continuous culture. J Bacteriol (2008) 1.17
Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob Agents Chemother (2006) 1.14
Laboratory diagnosis of human seasonal and pandemic influenza virus infection. Med J Aust (2006) 1.13
Influenza viruses with reduced sensitivity to the neuraminidase inhibitor drugs in untreated young children. Commun Dis Intell Q Rep (2008) 1.13
Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J Virol (2013) 1.11
Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1. J Infect Dis (2013) 1.10
CD4+ CD25+ regulatory T cells modulate the T-cell and antibody responses in helicobacter-infected BALB/c mice. Infect Immun (2006) 1.08
Annual report of the National Influenza Surveillance Scheme, 2007. Commun Dis Intell Q Rep (2008) 1.06
Rapid detection of the H275Y oseltamivir resistance mutation in influenza A/H1N1 2009 by single base pair RT-PCR and high-resolution melting. PLoS One (2011) 1.02
Rapid detection and subtyping of human influenza A viruses and reassortants by pyrosequencing. PLoS One (2011) 1.00
Development of an enzyme-linked immunoassay for the quantitation of influenza haemagglutinin: an alternative method to single radial immunodiffusion. Influenza Other Respir Viruses (2012) 1.00
Incidence of pandemic (H1N1) 2009 influenza infection in children and pregnant women during the 2009 influenza season in Western Australia - a seroprevalence study. Med J Aust (2011) 0.99
Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques. J Virol (2013) 0.99
Detection of evolutionarily distinct avian influenza a viruses in antarctica. MBio (2014) 0.98
Pandemic (H1N1) 2009 risk for frontline health care workers. Emerg Infect Dis (2011) 0.97
Progressive emergence of an oseltamivir-resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient. Influenza Other Respir Viruses (2013) 0.96
Rate of decline of antibody titers to pandemic influenza A (H1N1-2009) by hemagglutination inhibition and virus microneutralization assays in a cohort of seroconverting adults in Singapore. BMC Infect Dis (2014) 0.95
The recent establishment of North American H10 lineage influenza viruses in Australian wild waterfowl and the evolution of Australian avian influenza viruses. J Virol (2013) 0.95
Factors influencing infection by pandemic influenza A(H1N1)pdm09 over three epidemic waves in Singapore. Influenza Other Respir Viruses (2013) 0.93
Influenza antiviral resistance in the Asia-Pacific region during 2011. Antiviral Res (2012) 0.93
Laboratory-based influenza surveillance in New Caledonia, 1999-2003. Trans R Soc Trop Med Hyg (2005) 0.92
Vaccination with recombinant adhesins from the RgpA-Kgp proteinase-adhesin complex protects against Porphyromonas gingivalis infection. Vaccine (2006) 0.91
Development and comparison of molecular assays for the rapid detection of the pandemic influenza A (H1N1) 2009 virus. J Med Virol (2010) 0.91
Higher than expected seasonal influenza activity in Victoria, 2007. Commun Dis Intell Q Rep (2008) 0.91
Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring. Euro Surveill (2015) 0.90
Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses. Emerg Infect Dis (2012) 0.90
In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors. Antiviral Res (2004) 0.90
Reducing uncertainty in within-host parameter estimates of influenza infection by measuring both infectious and total viral load. PLoS One (2013) 0.90
Influenza outbreaks during World Youth Day 2008 mass gathering. Emerg Infect Dis (2010) 0.89
Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. Antiviral Res (2010) 0.88
Transmission of influenza A(H1N1) 2009 pandemic viruses in Australian swine. Influenza Other Respir Viruses (2012) 0.88
Universal influenza B virus genomic amplification facilitates sequencing, diagnostics, and reverse genetics. J Clin Microbiol (2014) 0.87
Tolerance induction using lentiviral gene delivery delays onset and severity of collagen II arthritis. Mol Ther (2009) 0.86
Seroepidemiologic effects of influenza A(H1N1)pdm09 in Australia, New Zealand, and Singapore. Emerg Infect Dis (2013) 0.85
Annual report of the National Influenza Surveillance Scheme, 2008. Commun Dis Intell Q Rep (2010) 0.85
Annual report of the National Influenza Surveillance Scheme, 2006. Commun Dis Intell Q Rep (2007) 0.84
Peramivir and laninamivir susceptibility of circulating influenza A and B viruses. Influenza Other Respir Viruses (2014) 0.84
Control of pandemic (H1N1) 2009 influenza virus infection of ferret lungs by non-adjuvant-containing pandemic and seasonal vaccines. Vaccine (2012) 0.83
The use of pyrosequencer-generated sequence-signatures to identify the influenza B-lineage and the subclade of the B/Yamataga-lineage viruses from currently circulating human influenza B viruses. J Clin Virol (2013) 0.83
Immunopathogenesis, loss of T cell tolerance and genetics of autoimmune gastritis. Autoimmun Rev (2002) 0.82
Annual report of the National Influenza Surveillance Scheme, 2005. Commun Dis Intell Q Rep (2006) 0.81
Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia. Commun Dis Intell Q Rep (2003) 0.81
A comparison of a rapid test for influenza with laboratory-based diagnosis in a paediatric population. Commun Dis Intell Q Rep (2005) 0.78
Influenza antivirals and resistance: the next 10 years? Expert Rev Anti Infect Ther (2012) 0.78
Teacher led school-based surveillance can allow accurate tracking of emerging infectious diseases - evidence from serial cross-sectional surveys of febrile respiratory illness during the H1N1 2009 influenza pandemic in Singapore. BMC Infect Dis (2012) 0.78
Seroprevalence of seasonal and pandemic influenza a in Kuala Lumpur, Malaysia in 2008-2010. J Med Virol (2013) 0.78
A novel means of identifying the neuraminidase type of currently circulating human A(H1) influenza viruses. Virus Res (2004) 0.78
Molecular epidemiology of influenza A(H1N1)pdm09 virus among humans and swine, Sri Lanka. Emerg Infect Dis (2014) 0.76
No association between mannose-binding lectin deficiency and H1N1 2009 infection observed during the first season of this novel pandemic influenza virus. Hum Immunol (2011) 0.76
Double dose oseltamivir for severe influenza--does it help? BMJ (2013) 0.75
Emergence of Influenza A(H7N4) Virus, Cambodia. Emerg Infect Dis (2019) 0.75
Addendum to Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level. Emerg Infect Dis (2022) 0.75